This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
Allele-Selective Inhibitors for Expanded Trinucleotide Repeat Genes Investments < €500k United States of America 2016
Prokineticin 2 and Neuroinflammatory Mechanisms Investments < €500k United States of America 2016
Synaptic toxicity of Huntington disease protein Investments < €500k United States of America 2016
BDNF rs6265 and Response to Dopaminergic Therapy in PD Investments < €500k United States of America 2016
Defining the mechanistic basis of a prion disaggregase Investments < €500k United States of America 2016
Role of Mitophagy in Mitochondrial Protein Quality Control Investments < €500k United States of America 2016
Capacity building in sub-Saharan Africa to conduct cutting-edge genetics research in Parkinsons disease. Investments < €500k United States of America 2016
Small molecule Parkin activators to treat Alzheimers Disease Investments < €500k United States of America 2016
ROS driven mitochondrial-telomere dysfunction during environmental stress Investments < €500k United States of America 2016
Patient Motor Neuron Assay System for ALS Drug Discovery Investments < €500k United States of America 2016
TDP-43 aggregation inhibitors for the treatment of ALS Investments < €500k United States of America 2016
A Novel Image Guided System to Mount Micro Targeting Platform for Deep Brain Stimulation Surgery to treat Parkinsons Disease Investments < €500k United States of America 2016
Retinal neurotoxicity of manganese exposure Investments < €500k United States of America 2016
Optimization of Bi-Pap and PEG intervention protocols for Amyotrophic Lateral Sclerosis Investments < €500k United States of America 2016
A synthetic vesicle to carry modifier compounds to axonal blocks induced by pathogenic polyQ Investments < €500k United States of America 2016
Development of a New ALS Mouse Model that Targets Profilin1 and Actin Filaments Investments < €500k United States of America 2016
Exploring and enhancing Karyopherin beta-2 disaggregate activity Investments < €500k United States of America 2016
Evaluating AAV-mediated gene replacement for Spinal Muscular Atrophy with Respiratory Distress 1 Investments < €500k United States of America 2016
Development of mouse models for ALS5 and SPG11 Investments < €500k United States of America 2016
Noninvasive High-resolution Pediatric Surface EMG Investments < €500k United States of America 2016
Alpha-Galactosidase A: a novel target for reducing alpha-synuclein toxicity Investments < €500k United States of America 2016
Pathogenic role of the novel mitochondrial apoptotic protein PSAP in ALS Investments < €500k United States of America 2016
Glial uptake of dopamine after L-DOPA medication Investments < €500k United States of America 2016
Autophagy dysfunction in Parkinsons Disease by VPS35 D620N Investments < €500k United States of America 2016
Neural Substrates of Deterministic Decision Making Investments < €500k United States of America 2016
HOT-ROXS: An integrated platform for identifying activators of non-druggable targets using biophysical screening, x-ray solution scattering and high-throughput co-crystallization Investments < €500k United States of America 2016
Development of protein molecular probes for detection of alpha synuclein oligomeric assemblies Investments < €500k United States of America 2016
Modifiers of C9orf72 associated dipeptide protein toxicity in a C. elegans model Investments < €500k United States of America 2016
Airway protection deficits according to stimulus type in Parkinsons disease Investments < €500k United States of America 2016
NOVEL EXPERIMENTAL PLATFORM FOR PRODOMAL PARKINSONS DISEASE Investments < €500k United States of America 2016
Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinsons Therapeutic Investments < €500k United States of America 2016
Striatal CaV1.3 Calcium Channels: An Overlooked Antidyskinetic Target for PD Investments < €500k United States of America 2016
Understanding the Voice Control System in Parkinsons Disease Investments < €500k United States of America 2016
MOLECULAR ORCHESTRATION OF MITOCHONDRIAL FITNESS VIA REPLACEMENT OR REPAIR Investments < €500k United States of America 2016
Efficacies and Pharmacodynamic Assays for LRRK2 Small-Molecule Inhibitors Investments < €500k United States of America 2016
Mechanisms Mediating NMJ Dennervation Investments < €500k United States of America 2016
Alpha-synuclein is crucial for neuronal function and survival-Characterization of a novel conditional alpha-synuclein knockout mouse model Investments < €500k United States of America 2016
Post-PT Extension of In-Home Dynamic Standing Table Use in Parkinson Disease Investments < €500k United States of America 2016
Statistical Methods for Causal Inference in Observational Studies Investments < €500k United States of America 2016
Mechanisms of C9orf72-associated dipeptide toxicity Investments < €500k United States of America 2016
Modeling Synaptic Vulnerability of a Brainstem Sensorimotor Circuit in a Mouse Model for Amyotrophic Lateral Sclerosis Investments < €500k United States of America 2016
Nanofibrous Scaffolds for Transplantation of Human Dopaminergic Neurons Investments < €500k United States of America 2016
Indices of Motor Synergies as Early Biomarkers of Parkinsons Disease Investments < €500k United States of America 2016
Molecular neuropathology of TDP-43 proteinopathies Investments < €500k United States of America 2016
Characterizing Intrinsic Functional Cortical Networks in Parkinson Disease Dementia Investments < €500k United States of America 2016
EPIGENETIC AND MRNA PROFILING OF STRIATOPALLIDAL NEURONS IN HUNTINGTONS DISEASE Investments < €500k United States of America 2016
Development of DNAzyme Gene Therapy for Huntingtons Disease Investments < €500k United States of America 2016
Exercise Intervention for Slowing HD Progression Investments < €500k United States of America 2016
Lysosomal stress triggers exosome release and transfer of proteins Investments < €500k United States of America 2016
Mechanisms of alpha-synuclein accumulation in traumatic brain injury (R21 NS094908 Resubmission) Investments < €500k United States of America 2016
